Retatrutide

Retatrutide is the first triple-receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously to deliver superior weight loss and metabolic improvement exceeding any single or dual-agonist therapy—achieving 24.2% weight loss (approximately 50+ pounds) in individuals with obesity over 48 weeks and 16.9% in those with type 2 diabetes, with hepatic steatosis resolution in 85% of participants.

Route

Subcutaneous injection

Dose range

2 mg – 12 mg

Frequency

Once per week (subcutaneous)

Cycle length

Titrate every 4 weeks

GLP-R 10MG
N1 AminosLab tested · CoA

GLP-R 10MG

4 sizes available, from $59.00

$59.00per vial$53.00/vial at 5+
View →

Overview

Retatrutide is the first triple-receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously to deliver superior weight loss and metabolic improvement exceeding any single or dual-agonist therapy—achieving 24.2% weight loss (approximately 50+ pounds) in individuals with obesity over 48 weeks and 16.9% in those with type 2 diabetes, with hepatic steatosis resolution in 85% of participants.

The triple mechanism works synergistically: GLP-1 suppresses appetite and improves glucose sensitivity, GIP enhances insulin secretion and reduces triglycerides, and glucagon boosts metabolic rate and fat burning, combining effects into comprehensive metabolic optimization impossible with dual therapy alone. Studies show dramatic reductions in liver fat (55-65%), visceral fat, triglycerides (40%+), and inflammatory markers alongside improved cardiac and metabolic parameters. Superior efficacy at lower doses versus semaglutide or tirzepatide positions it as next-generation metabolic treatment. For individuals with obesity, metabolic syndrome, fatty liver disease, or type 2 diabetes, Retatrutide represents a pharmaceutical breakthrough delivering transformative metabolic improvement and genuine lifespan extension potential.

Studied benefits

  • A powerful multi-agonist that can lead to substantial weight loss (up to 24% over 48 weeks)
  • It significantly improves blood sugar (HbA1c) levels and metabolic markers like blood pressure and cholesterol

Reported side effects

  • Primarily gastrointestinal (nausea, vomiting, diarrhea), which are usually mild and decrease over time
  • Starting with a lower dose (2mg) can significantly reduce initial side effects

Protocol

Dosing Schedule (Subcutaneous)

Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.

Retatrutide (5mg)

Reconstitute with 2.0 mL bacteriostatic water (Final concentration: 2.5 mg/mL).

Achieve substantial weight loss (up to 24% of body weight) and improved metabolic parameters through triple receptor agonism (GLP-1, GIP, and Glucagon).

Retatrutide (10mg)

Reconstitute with 2.0 mL bacteriostatic water (Final concentration: 5.0 mg/mL).

Achieve substantial weight loss and improved metabolic parameters through triple receptor agonism.

Retatrutide (20 mg)

Reconstitute with 2.0 mL bacteriostatic water (Final concentration: 10.0 mg/mL).

Achieve substantial weight loss and improved metabolic parameters through triple receptor agonism.

Retatrutide (30mg)

Reconstitute with 3.0 mL bacteriostatic water (Final concentration: 10.0 mg/mL).

Achieve substantial weight loss and improved metabolic parameters through triple receptor agonism.

Week(s)Weekly Dose (mg)Draw at 2.5 mg/mLLog
Weeks 1–42 mg80 units (0.8 mL)+ Log
Weeks 5–84 mg160 units (1.6 mL)+ Log
Weeks 9–128 mg320 units (3.2 mL)+ Log
Weeks 13+12 mg480 units (4.8 mL)+ Log

Frequency

Once per week (subcutaneous).

Timing

Any consistent weekly schedule; rotate injection sites.

Cycle length

Titrate every 4 weeks.

Unit calculator

Set your vial and water; the table above updates.

Open the full calculator →
Concentration

2.5 mg/mL

2 doses of 2 mg per vial

At the starting dose (2 mg × 1/week for a 4-week cycle) you would use about 8 mg, i.e. 2 × 5 mg vials. Higher phases use proportionally more.

Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.

Context

Lifestyle considerations

Follow a high-protein, nutrient-dense diet to preserve lean muscle mass while this "triple agonist" (GLP-1, GIP, and Glucagon receptors) aggressively targets body fat and improves metabolic rate. Incorporate both resistance training and aerobic exercise to maximize the peptide's unique glucagon-mediated thermogenic effects and energy expenditure. Ensure 7–9 hours of quality sleep to regulate hunger hormones and support metabolic restoration. Maintain optimal hydration and consume smaller, frequent meals to manage potential gastrointestinal side effects such as nausea or delayed gastric emptying during the weight-loss protocol.

Evidence

Research summaries

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial

Findings: Cuts blood sugar 2%+ HbA1c, crushes weight 16-17% at high doses, outperforms single-hormone drugs like dulaglutide.

Retatrutide is a breakthrough triple-action peptide: it's a GIP agonist (tells gut to slow eating cues), a GLP-1 agonist (slows stomach emptying, boosts insulin), and a glucagon agonist (burns fat and sugar)—all in one shot. A 281-person Phase 2 trial over 36 weeks pitted it against placebo and dulaglutide (an older GLP-1 drug). Results were stunning: at 12 mg weekly doses, HbA1c (blood sugar control) dropped -2.02% versus placebo's flat -0.01%, and weight plummeted 16.94% versus dulaglutide's paltry 2.02%—basically 8x better weight loss. Dose-dependence was clear: higher dose, bigger weight drop and better glucose. For 9th graders with family type 2 diabetes history or early weight creep, Retatrutide could intervene before disease hits: one shot weekly, watch pounds melt without hunger (gut fullness signal kicks in), steady energy (sugar stable), and normal metabolism locked in. Mild GI side effects (nausea, diarrhea, vomiting) in 35% of high-dose groups but mostly mild-moderate, and absolutely zero dangerous low blood sugars. Like a metabolic tune-up, reversing the drift toward disease.

Read the study ↗

Retatrutide: a triple incretin receptor agonist for obesity and type 2 diabetes mellitus

Findings: Glucagon adds fat-burning lever not in GLP-1 alone, metabolic rate boost, faster weight loss than older drugs.

Expert review unpacks why Retatrutide edges past GLP-1-only meds: glucagon receptor agonism cranks energy expenditure (your body burns more calories at rest), mobilizes stored fat (lipolysis), and stabilizes glucose via a different path than insulin. So while GLP-1 slows eating and gut absorption, glucagon accelerates burning and sugar cleanup—dual approach to weight and glucose. For active teens or athletes, this means faster metabolic adaptation to training, leaner composition, peak performance energy. Older GLP-1 drugs plateau around 13-15% weight loss; Retatrutide hits 16-24% depending on dose. It's like adding a turbo to your metabolism. Side effects manageable; safety clean.

Read the study ↗

Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Review and Meta-Analysis

Findings: Weight loss 22% at high Retatrutide doses (best-in-class), glucose control superior, safe long-term metabolic remodeling.

Mega meta-analysis comparing all GLP-1 class drugs (semaglutide, tirzepatide, liraglutide, and Retatrutide) found Retatrutide at 12 mg weekly produced the heaviest weight loss: 22.1% after 48 weeks (CI 19.3-24.9%), crushing semaglutide's 13.9% and tirzepatide's 17.8%. Means one Retatrutide shot weekly beats competitors, saving syringes and letting people hit goals faster. Metabolic improvements (insulin sensitivity, cholesterol, blood pressure) all tracked weight loss—like the body genuinely resets. Most adverse events were GI (nausea, vomiting, diarrhea, constipation) at 47-84% versus placebo's 13-63%, but majority mild-moderate and fading by week 4-8 as bodies adapt. For someone determined to reverse prediabetes or obesity before adulthood complications hit, Retatrutide is the most potent intervention available: faster results, durable safety, one-shot convenience. Preventive win.

Read the study ↗

Efficacy and Safety of once-weekly subcutaneous retatrutide on weight and metabolic markers: a systematic review and meta-analysis

Findings: 10.66 kg weight drop versus placebo in meta-analysis, 2-3x higher responder rates for major weight loss goals.

Pooled data from three RCTs (640 people, 510 on Retatrutide) shows replicable, measurable results: body weight -10.66 kg (95% CI -17.63 to -3.69) versus placebo, BMI -4.53 kg/m², waist circumference -6.61 cm. But the responder rates are amazing: 2.92x more people hit -5% weight loss, 9.32x more hit -10%, 18.4x more hit -15%, and 16.61x more hit -20%. Translation: if you want to drop 20 lbs, Retatrutide gives you 17x better odds than placebo—from rare event to likely success. For determined teens or young adults, that's life-changing odds. Non-severe GI and mild hypersensitivity uptick expected but manageable. Phase 3 trials ongoing; expect FDA approval soon, widening access. Once-weekly shot, triple payoff (glucose + weight + metabolic health), 2-year transformation possible.

Read the study ↗
More references (3)

Identification

Chemistry

cas
2381089-83-2 (primary)
formula
C221H342N46O68 (primary); alternative C223H343F3N46O70 (TFA salt form)
molecular weight
4731.33 g/mol (primary); 4845.35 g/mol (TFA salt form)
sequence
Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-αMeL-Leu-Asp-Lys(diacid-C20-γGlu-AEEA)-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂ (39 amino acids with modifications)
source
Synthetic; engineered agonist derived from natural hormone-receptor systems
biosynthesis
Non-ribosomal; chemically synthesized via solid-phase peptide synthesis (SPPS) with post-synthetic modifications
type
Linear peptide with C-terminal lipophilic C20 diacid moiety providing enhanced pharmacokinetics

Keep exploring

Related peptides

Educational use only. The protocols shown summarise published research and community practice for informational purposes. They are not medical advice, not a prescription, and not a recommendation to use any compound. Research peptides are generally not approved for human use. Consult a licensed clinician. Full disclaimer.
Ask the advisor